Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the stock in a transaction on Monday, April 20th. The stock was sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the sale, the chief executive officer directly owned 1,647,546 shares in the company, valued at $48,750,886.14. This trade represents a 10.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Venker also recently made the following trade(s):
- On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $28.24, for a total transaction of $5,648,000.00.
- On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00.
Roivant Sciences Stock Performance
Shares of NASDAQ ROIV opened at $29.15 on Thursday. The company's fifty day moving average price is $28.19 and its 200 day moving average price is $23.47. Roivant Sciences Ltd. has a 1 year low of $10.57 and a 1 year high of $30.33. The company has a market capitalization of $20.86 billion, a PE ratio of -24.91 and a beta of 1.20.
Analyst Ratings Changes
ROIV has been the topic of a number of recent analyst reports. Weiss Ratings downgraded shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, February 9th. Citigroup upped their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a "buy" rating in a research report on Tuesday, February 10th. Piper Sandler upped their price objective on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an "overweight" rating in a research report on Thursday, April 16th. HC Wainwright upped their price objective on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. Finally, Guggenheim upped their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences presently has an average rating of "Moderate Buy" and an average price target of $30.55.
Check Out Our Latest Analysis on Roivant Sciences
Institutional Investors Weigh In On Roivant Sciences
A number of hedge funds have recently modified their holdings of the business. Fifth Third Wealth Advisors LLC raised its position in shares of Roivant Sciences by 4.6% in the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock valued at $282,000 after buying an additional 445 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company's stock valued at $1,891,000 after buying an additional 500 shares during the last quarter. Bank of Montreal Can raised its position in shares of Roivant Sciences by 1.3% in the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company's stock valued at $868,000 after buying an additional 516 shares during the last quarter. Bessemer Group Inc. raised its position in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock valued at $28,000 after buying an additional 543 shares during the last quarter. Finally, Allworth Financial LP raised its position in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
